Susanna Giordano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Susanna Giordano has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Francesco Giuseppe De Rosa
Infectious Diseases Unit Cardinal Massaia Hospital Asti Italy
2 shared publications- Luigi Cattel
Department of Drug Science and Technology University of Turin Turin Italy
2 shared publications Silvia Corcione
Department of Medical Sciences Tufts University School of Medicine Boston Massachusetts USA
2 shared publicationsAnnalisa Ferrero
Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, Via P. Giuria 9, 10125 Torino, Italy
1 shared publication- Barbara Stella
Department of Drug Science and Technology University of Turin Turin Italy
1 shared publication - Carla Maria Zotti
Department of Public Health and Paediatrics, University of Turin, Via Santena 5 bis, 10126 Turin, Italy
1 shared publication
Latest Publications
- Open Access
- 20 May 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (5) , 695
An Observational Study of MDR Hospital-Acquired Infections and Antibiotic Use during COVID-19 Pandemic: A Call for Antimicrobial Stewardship Programs
The pandemic caused by the COVID-19 virus has required major adjustments to healthcare systems, especially to infection control and antimicrobial stewardship. The objective of this study was to describe the incidence of multidrug-resistant (MDR) hospital-acquired infections (HAIs) and antibiotic consumption during the three waves of COVID-19 and to compare it to the period before the outbreak at Molinette Hospital, located in the City of Health and Sciences, a 1200-bed teaching hospital with surgical, medical, and intensive care units. We demonstrated an increase in MDR infections: particularly in K. pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp), A. baumannii, and MRSA. Fluoroquinolone use showed a significant increasing trend in the pre-COVID period but saw a significant reduction in the COVID period. The use of fourth- and fifth-generation cephalosporins and piperacillin–tazobactam increased at the beginning of the COVID period. Our findings support the need for restoring stewardship and infection control practices, specifically source control, hygiene, and management of invasive devices. In addition, our data reveal the need for improved microbiological diagnosis to guide appropriate treatment and prompt infection control during pandemics. Despite the infection control practices in place during the COVID-19 pandemic, invasive procedures in critically ill patients and poor source control still increase the risk of HAIs caused by MDR organisms.
- 20 May 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (5) , 695
Open AccessAn Observational Study of MDR Hospital-Acquired Infections and Antibiotic Use during COVID-19 Pandemic: A Call for Antimicrobial Stewardship Programs
The pandemic caused by the COVID-19 virus has required major adjustments to healthcare systems, especially to infection control and antimicrobial stewardship. The objective of this study was to describe the incidence of multidrug-resistant (MDR) hospital-acquired infections (HAIs) and antibiotic consumption during the three waves of COVID-19 and to compare it to the period before the outbreak at Molinette Hospital, located in the City of Health and Sciences, a 1200-bed teaching hospital with surgical, medical, and intensive care units. We demonstrated an increase in MDR infections: particularly in K. pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp), A. baumannii, and MRSA. Fluoroquinolone use showed a significant increasing trend in the pre-COVID period but saw a significant reduction in the COVID period. The use of fourth- and fifth-generation cephalosporins and piperacillin–tazobactam increased at the beginning of the COVID period. Our findings support the need for restoring stewardship and infection control practices, specifically source control, hygiene, and management of invasive devices. In addition, our data reveal the need for improved microbiological diagnosis to guide appropriate treatment and prompt infection control during pandemics. Despite the infection control practices in place during the COVID-19 pandemic, invasive procedures in critically ill patients and poor source control still increase the risk of HAIs caused by MDR organisms.
- Open Access
- 11 November 2021
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (3) , 878-896
Vaccine development and technology for SARS‐CoV‐2: Current insight
Severe acute respiratory syndrome coronavirus 2 is associated with a severe respiratory disease in China, that rapidly spread across continents. Since the beginning of the pandemic, available data suggested the asymptomatic transmission and patients were treated with specific drugs with efficacy and safety data not always satisfactory. The aim of this review is to describe the vaccines developed by three companies, Pfizer‐BioNTech, Moderna, and University of Oxford/AstraZeneca, in terms of both technological and pharmaceutical formulation, safety, efficacy, and immunogenicity. A critical analysis of Phases 1, 2, and 3 clinical trial results available was conducted, comparing the three vaccine candidates, underlining their similarities and differences. All candidates showed consistent efficacy and tolerability; although some differences can be noted, such as their technological formulation, temperature storage, which will be related to logistics and costs. Further studies will be necessary to evaluate long‐term effects and to assess the vaccine safety and efficacy in the general population.
- 11 November 2021
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (3) , 878-896
Open AccessVaccine development and technology for SARS‐CoV‐2: Current insight
Severe acute respiratory syndrome coronavirus 2 is associated with a severe respiratory disease in China, that rapidly spread across continents. Since the beginning of the pandemic, available data suggested the asymptomatic transmission and patients were treated with specific drugs with efficacy and safety data not always satisfactory. The aim of this review is to describe the vaccines developed by three companies, Pfizer‐BioNTech, Moderna, and University of Oxford/AstraZeneca, in terms of both technological and pharmaceutical formulation, safety, efficacy, and immunogenicity. A critical analysis of Phases 1, 2, and 3 clinical trial results available was conducted, comparing the three vaccine candidates, underlining their similarities and differences. All candidates showed consistent efficacy and tolerability; although some differences can be noted, such as their technological formulation, temperature storage, which will be related to logistics and costs. Further studies will be necessary to evaluate long‐term effects and to assess the vaccine safety and efficacy in the general population.
- 1 January 2021
- Published by Elsevier in Virus Research
- Vol. 291, 198207
Ozone therapy in COVID-19: A narrative review
- 1 January 2021
- Published by Elsevier in Virus Research
- Vol. 291, 198207
Ozone therapy in COVID-19: A narrative review
- Open Access
- 1 January 2013
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 440 (2) , 221-228
Ruthenium polypyridyl squalene derivative: A novel self-assembling lipophilic probe for cellular imaging
- 1 January 2013
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 440 (2) , 221-228
Open AccessRuthenium polypyridyl squalene derivative: A novel self-assembling lipophilic probe for cellular imaging